Literature DB >> 12615650

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course.

Ferdinando Squitieri1, Cinzia Gellera, Milena Cannella, Caterina Mariotti, Giuliana Cislaghi, David C Rubinsztein, Elisabeth W Almqvist, David Turner, Anne-Catherine Bachoud-Lévi, Sheila A Simpson, Martin Delatycki, Vittorio Maglione, Michael R Hayden, Stefano Di Donato.   

Abstract

Huntington disease is caused by a dominantly transmitted CAG repeat expansion mutation that is believed to confer a toxic gain of function on the mutant protein. Huntington disease patients with two mutant alleles are very rare. In other poly(CAG) diseases such as the dominant ataxias, inheritance of two mutant alleles causes a phenotype more severe than in heterozygotes. In this multicentre study, we sought differences in the disease features between eight homozygotes and 75 heterozygotes for the Huntington disease mutation. We identified subjects homozygous for the Huntington disease mutation by DNA testing and compared their clinical features (age at onset, symptom presentation, disease severity and disease progression) with those of a group of heterozygotes, who were assessed longitudinally. The age at onset of symptoms in the homozygote cases was within the range expected for heterozygotes with the same CAG repeat lengths, whereas homozygotes had a more severe clinical course. The observation of a more rapid decline in motor, cognitive and behavioural symptoms in homozygotes was consistent with the extent of neurodegeneration as available at imaging in three patients, and at the post-mortem neuropathological report in one case. Our analysis suggests that although homozygosity for the Huntington disease mutation does not lower the age at onset of symptoms, it affects the phenotype and the rate of disease progression. These data, once confirmed in a larger series of patients, point to the possibility that the mechanisms underlying age at onset and disease progression in Huntington disease may differ.

Entities:  

Mesh:

Year:  2003        PMID: 12615650     DOI: 10.1093/brain/awg077

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  51 in total

1.  Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.

Authors:  Ferdinando Squitieri; Vittorio Maglione; Sara Orobello; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2011-04-26       Impact factor: 3.575

2.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

3.  Key role of nuclear medicine in seeking biomarkers of Huntington's disease.

Authors:  Ferdinando Squitieri; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

4.  Raft-like microdomains play a key role in mitochondrial impairment in lymphoid cells from patients with Huntington's disease.

Authors:  Laura Ciarlo; Valeria Manganelli; Paola Matarrese; Tina Garofalo; Antonella Tinari; Lucrezia Gambardella; Matteo Marconi; Maria Grasso; Roberta Misasi; Maurizio Sorice; Walter Malorni
Journal:  J Lipid Res       Date:  2012-07-06       Impact factor: 5.922

5.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

Review 6.  Neurodegenerative disorders: Parkinson's disease and Huntington's disease.

Authors:  S M Hague; S Klaffke; O Bandmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

7.  Neurodegenerative disease: Tracking disease progress in Huntington disease.

Authors:  Roger A Barker; Sarah L Mason
Journal:  Nat Rev Neurol       Date:  2011-03-15       Impact factor: 42.937

8.  Abnormal morphology of peripheral cell tissues from patients with Huntington disease.

Authors:  Ferdinando Squitieri; Alessandra Falleni; Milena Cannella; Sara Orobello; Federica Fulceri; Paola Lenzi; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2009-10-16       Impact factor: 3.575

9.  Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.

Authors:  Ferdinando Squitieri; Sara Orobello; Milena Cannella; Tiziana Martino; Pantaleo Romanelli; Giampiero Giovacchini; Luigi Frati; Luigi Mansi; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-11       Impact factor: 9.236

Review 10.  Huntington's Disease: Relationship Between Phenotype and Genotype.

Authors:  Yi-Min Sun; Yan-Bin Zhang; Zhi-Ying Wu
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.